With Academic Funding, GSK Looks to Zap Life Into Electroceuticals
This article was originally published in The Pink Sheet Daily
By seeding exploratory lab work across several biomedical and engineering disciplines, GlaxoSmithKline wants to understand how neural signals regulate diseases and eventually to design devices that can alter signals and provide therapeutic benefit.
You may also be interested in...
The British pharma has financed a new venture fund to create a presence in an emerging technology and help jump-start the fledgling industry because it believes that the science has reached a transition point.
The biotech brings Roche on as its seventh biopharma partner, building on the more than $5 billion in potential partnership revenue the biotech had already amassed. If all goes as planned, Isis will add five marketed products within the next five years to the newly approved Kynamro. But Wall Street doesn’t expect Isis’ revenues to increase much anytime soon. Plus more notable deals this week…